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Abstract
Stem cells are a relevant source of information about cellular differentiation, molecular processes and tissue
homeostasis, but also one of the most putative biological tools to treat degenerative diseases. This review focuses
on human stem cells clinical and experimental applications. Our aim is to take a correct view of the available stem
cell subtypes and their rational use in the medical area, with a specific focus on their therapeutic benefits and side
effects. We have reviewed the main clinical trials dividing them basing on their clinical applications, and taking into
account the ethical issue associated with the stem cell therapy.
Methods: We have searched Pubmed/Medline for clinical trials, involving the use of human stem cells, using the
key words “stem cells” combined with the key words “transplantation”, “pathology”, “guidelines”, “properties” and
“risks”. All the relevant clinical trials have been included. The results have been divided into different categories,
basing on the way stem cells have been employed in different pathological conditions.
Introduction
The word “stemness” defines a series of properties
which distinguish a heterogeneous variety of cell popula-
tion. However, in the absence of a current consensus on
a gold standard protocol to isolate and identify SCs, the
definition of “stemness” is in a continuous evolution
[1-3].
Biologically, stem cells (SCs) are characterized by self-
renewability [4], that is the ability not only to divide
themselves rapidly and continuously, but also to create
new SCs and progenitors more differentiated than the
mother cells. The asymmetric mitosis is the process
which permits to obtain two intrinsically different
daughter cells. A cell polarizes itself, so that cell-fate
determinant molecules are specifically localized on one
side. After that, the mitotic spindle aligns itself perpen-
dicularly to the cell axis polarity. At the end of the pro-
cess two different cells are obtained [5-7].
SCs show high plasticity, i.e. the complex ability to
cross lineage barriers and adopt the expression profile
and functional phenotypes of the cells that are typical
of other tissues. The plasticity can be explained by
transdifferentiation (direct or indirect) and fusion.
Transdifferentiation is the acquisition of the identity of
a different phenotype through the expression of the
gene pattern of other tissue (direct) or through the
achievement of a more primitive state and the succes-
sive differentiation to another cell type (indirect or de-
differentiation). By fusion with a cell of another tissue, a
cell can express a gene and acquire a phenotypic ele-
ment of another parenchyma [3].
SCs morphology is usually simpler than that one of
the committed cells of the same lineage. It has often got
a circular shape depending on its tissue lineage and a
low ratio cytoplasm/nucleus dimension, i.e. a sign of
synthetic activity. Several specifics markers of general or
lineage “stemness” have been described but some, such
as alkaline phosphatase, are common to many cell types
[1,8-11].
From the physiological point of view, adult stem cells
(ASCs) maintain the tissue homeostasis as they are
already partially committed. ASCs usually differentiate
in a restricted range of progenitors and terminal cells to
replace local parenchyma (there is evidence that trans-
differentiation is involved in injury repair in other dis-
tricts [12], damaged cells or sustaining cellular turn over
[13]). SCs derived from early human embryos (Embryo-
nic stem cells (ESCs)), instead, are pluripotent and can
generate all committed cell types [14,15]. Fetal stem
cells (FSCs) derive from the placenta, membranes,
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amniotic fluid or fetal tissues. FSCs are higher in num-
ber, expansion potential and differentiation abilities if
compared with SCs from adult tissues [16]. Naturally,
the migration, differentiation and growth are mediated
by the tissue, degree of injury and SCs involved.
Damaged tissue releases factors that induce SCs homing.
The tissue, intended as stromal cells, extracellular
matrix, circulating growth and differentiating factors,
determines a gene activation and a functional reaction
on SCs, such as moving in a specific district, differen-
tiating in a particular cell type or resting in specific
niches. These factors can alter the gene expression pat-
tern in SCs when they reside in a new tissue [17].
Scientific research has been working to understand
and to indentify the molecular processes and cellular
cross-talking that involve SCs. Only with a deep knowl-
edge of the pathophysiological mechanism involving
SCs, we might be able to reproduce them in a labora-
tory and apply the results obtained in the treatment of
degenerative pathologies, i.e. neurological disorder such
as Parkinson’s disease (PD), Alzheimer’s disease (AD),
Huntington’s disease, multiple sclerosis [18], musculos-
keletal disorder [19], diabetes [20], eye disorder [21],
autoimmune diseases [22], liver cirrhosis [23], lung dis-
ease [24] and cancer [25].
In spite of the initial enthusiasm for their potential
therapeutic application, SCs are associated with several
burdens that can be observed in clinical practice. Firstly,
self-renewal and plasticity are properties which also
characterize cancer cells and the hypothesis to lose con-
trol on transplanted SCs, preparing a fertile ground for
tumor development, is a dangerous and unacceptable
side effect [26,27]. Secondly, in case of allogenic SCs
graft, several cases of immunorejection or graft versus
host disease [28] are reported, with a necessary immu-
nosuppressive treatment to avoid immune response
against the transplant and the consequent risk of infec-
tions. Finally, to succeed in ESCs cultures, it is necessary
to manipulate and to reproduce embryos for scientific
use, but the Catholic World identifies this stage of the
human development with birth and attributes embryos
the same rights [29].
Stem Cells Types
SCs are commonly defined as cells capable of self-renewal
through replication and differentiating into specific
lineages. Depending on “differentiating power”, SCs are
divided into several groups. The cells, deriving from an
early progeny of the zygote up to the eight cell stage of the
morula, are defined as “totipotent”, due to their ability to
form an entire organism [30]. The “pluripotent” cells, such
as ESCs, can generate the tissues of all embryonic germ
layers, i.e. endoderm, mesoderm, and ectoderm, while
“multipotent” cells, such as ASCs, are capable of yielding a
more restricted subset of cell lineages. Another type of
SCs classification is based on the developmental stage
from which they are obtained, i.e. embryonic origin (ESCs)
or postnatal derivation (ASCs) [3].
Embryo-derived stem cells
A zygote is the initial cell originating when a new
organism is produced by means of sexual reproduction.
Zygotes are usually produced by a fertilization event
between two haploid cells, i.e. an ovum from a female
and a sperm cell from a male, which combine to form
the single diploid cell [31].
The blastocyst is the preimplantation stage in embryos
aged one week approximately. The blastocyst is a cave
structure compound made by the trophectoderm, an
outer layer of cells filling cavity fluid and an inner cell
mass (ICM), i.e. a cluster of cells on the interior layer
[32-35].
Embryonic cells (EC, epiblast) are contained in the
ICM and generate the organism, whereas the surround-
ing trophoblast cells contribute to the placental chorion.
Traditionally, ECs are capable of a self-renewal and dif-
ferentiation into cells of all tissue lineages [15], but not
into embryonic annexes as such zygote. ECs can be cul-
tured and ESCs can be maintained for a long time (1-2
years with cell division every 36-48 hours) in an undiffer-
entiated phenotype [10,33,36] and which unchanged
properties. ECs can be isolated by physical micro dissec-
tion or by complement-mediated immune dissection.
ECs are preserved through fast freeze or vitrification
techniques to avoid an early natural differentiation
[37-39]. Culturing ESCs requires a special care, in fact,
under SCs, a feeder layer of primary murine fibroblast is
seeded in a permanent replication block that sustains
continuously undifferentiated ESCs [14]. ESCs are main-
tained for a long time in culture to obtain a large pool of
undifferentiated SCs for therapeutic and research appli-
cations. In contrast, somatic cells and mesenchimal stem
cells (MSCs) have finite replicative lifespan after which
they can no longer divide and are said to have reached a
proliferative senescence [40]. The replicative lifespan of
cells depends on the cell type, donor’s species, and
donor’s age, but it is directly related to telomerase activity
[41-44]. Telomerase is an enzyme which adds specific
short sequences to chromosomes ends, aiming at preser-
ving chromosome length and supporting the ongoing cell
division [42]. Telomerase activity is decreased by com-
mitting and, as a result, it is characteristically high in
ESCs, intermediate in haematopoietic stem cells (HSCs),
and variable, or even absent, in somatic cells [3,42].
Fetal stem cells
FSCs are multipotent cells with the same functional
properties of ASCs, but they locate in the fetal tissue
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and embryonic annexes. Indeed, further analyses are
necessary to investigate whether ASCs are the same pre-
sent in the tissue. FSCs have been subdivided into hae-
mopoietic ones, located in blood, liver, bone marrow
(BM), mesenchymal ones located in blood, liver, BM,
lung, kidney and pancreas, endothelial ones found in
BM and placenta, epithelial ones located in liver and
pancreas and neural ones located in brain and spinal
cord [45]. Obviously, the only source of FSCs, relatively
feasible and safe for fetus, is fetal blood [46]. Nowadays
a routine procedure for fetal diagnosis and therapy,
which are the most diffuse techniques to harvest FSCs,
is ultrasound guided accession to fetal circulation [45].
Adult stem cells
ASCs are partially committed SCs localized in specific
stromal niches. ASCs can be obtained from the meso-
dermal tissues such as BM [1,47], muscle [48], adipose
tissue [49], synovium [50] and periosteum [51]. SCs
have been also isolated from the tissues of endodermal
lineages such as intestine [52] and from the ectodermal
tissues including skin [53], deciduous teeth [54] and
nerve tissue [8,9,55,56]. ASCs originate during ontogen-
esis and remain in a marginal area in a quiescent state
as the local stimuli induce their cycle recruitment and
migration. In fact, niche microenvironment, with physi-
cal contact and chemical dialogue among SCs, stromal
cells and matrix, induce ASCs differentiation and self-
renewal [57,58].
Probably, for documented plasticity and easy extrac-
tion, several ASCs types, such as HSCs, adipose tissue-
derived stromal cells (ADSCs) and derived MSCs, have
had and have a historical importance. HSCs are well
characterized cells of mesodermal origin deriving preva-
lently from BM, in particular near endosteal bone sur-
face and sinusoidal endothelium and from peripheral
blood. Traditionally HSCs generate all mature blood cell
types of the hematolymphatic system including neutro-
phils, monocytes/macrophages, basophils, eosinophils,
erythrocytes, platelets, mast cells, dendritic cells, and B
and T lymphocytes. More recently, HSCs have shown to
display remarkable plasticity and can apparently differ-
entiate into several non-hemolymphatic tissue lineages
[3]. The identification and isolation of HSCs is possible
with immune capture of CD34, a surface protein that
distinguishes SCs from other hematopoietic cells [59].
HSCs are at the base of BM transplant procedures, i.e.
myeloablation or adiuvant therapy where HSCs are
infused in the recipient [60].
MSCs originally derive from BM, [1,8,47] but they have
been isolated from other tissues, such as adipose tissue,
periosteum, synovial membrane, synovial fluid (SF), mus-
cle, dermis, deciduous teeth, pericytes, trabecular bone,
infrapatellar fat pad, and articular cartilage [1,19,47,61-68].
They are generally restricted to forming only mesodermal-
specific cell types such as adipocytes, osteoblasts, myocytes
and chondrocytes, but several MSCs are able to differenti-
ate in cells of the three embryonic germ layers [69]. Sev-
eral of these studies report the differentiation of MSCs
into various tissue lineages in vitro and the repair or
“engraftment” of the damaged organs in vivo, such as
bone tissue repair and immune system reconstruction, but
they are even able to differentiate in endothelial cells and
contribute to revascularization of the ischemic tissue
[3,70,71]. In particular, recent studies show that cultured
MSCs secrete various bioactive molecules which have got
anti-apoptotic, immunomodulatory, angiogenic, anti-
scarring and chemo-attractant properties, providing a
basis for their use as tools to create local regenerative
environments in vivo [72].
Umbilical cord stem cells
In the umbilical cord, we can find two types of SC
sources, i.e. the umbilical cord epithelium (UCE),
derived from the amniotic membrane epithelium and
the umbilical cord blood (UCB) [73]. Although its gen-
eral architecture significantly differs from the mamma-
lian epidermis, UCE expresses a cytokeratin pattern
similar to human epidermis [74,75]. UCE is able to form
a stratified epithelium when seeded on fibroblast popu-
lated collagen gels [76,77]. It has been demonstrated
that UCE is an important source of the human primary
keratinocytes and it is able to recreate the epidermis for
dermatological application [78]. In UCB we can find two
different types of SCs, i.e. hematopoietic (UC-HS) and
mesenchymal (UC-MS). Although UCB SCs are biologi-
cally analogous to their adult counterpart, it has been
pointed out that UCB cells are characterized by a higher
immunological tolerance than their adult counterpart
[79]. Indeed UC-MS can produce cytokines which facili-
tate grafting in the donor, in vitro SC survival and it is
more efficient than BM MSC graft [80].
Risks And Obstacles To Stem Cells Application In
Clinical Practice
Risks
SC graft induces therapeutic and side effects. A specific
evaluation of the side effects is needed to decide if a
cure can be adopted in medical practice. Indeed, scienti-
fic research has to outline the severity of undesired
effects, their frequency in treated subjects and the possi-
bility to avoid, reduce or abate them. The major limita-
tions to the success of HSC transplantation (HSCT) are
respiratory complications and graft versus host disease.
Lung dysfunction occurs in up to 50% of the subjects
after HSCT, and pulmonary complications are among
the most common causes of morbidity and mortality
after this procedure.
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Obliterative bronchiolitis (OB) is a multifactorial pro-
cess involving both alloimmunologic and nonalloimmu-
nologic reactions as the heterogeneous histopathologic
findings and clinical course suggest. Since the occur-
rence of OB has been closely associated with GVHD, it
has been hypothesized that OB is mediated, partially, by
alloimmunologic injury to host bronchiolar epithelial
cells [81-83]. Usually, OB develops as a late complica-
tion, i.e. after the first 100 days, of HSCT. The OB
onset is usually 6-12 months post-transplant, with the
clinical seriousness ranging from asymptomatic severity
to a fulminant and fatal one. The pathogenesis of the
disease is believed to primarily involve the interplay
among immune effectors cells that have been recruited
from the lung and cells resident in the pulmonary vas-
cular endothelium and interstitium. This complex pro-
cess results in the loss of type I pulmonary epithelial
cells, a proliferation of type II cells, the recruitment and
proliferation of endothelial cells and the deposition of
the extracellular matrix. In response to the pattern of
injury, cytokines are released from immune effectors
cells and lung cells, i.e. macrophages, alveolar epithelial,
and vascular endothelial cells, and they can stimulate
the fibroblast proliferation and increase the synthesis of
collagen and extracellular matrix proteins. The result is
the large deposition of collagen and granulation tissue
in and around the bronchial structures, with the partial
or complete small airway obliteration. Clinical data sug-
gest that nonalloimmunologic inflammatory conditions,
such as viral infections, recurrent aspiration, and condi-
tioning chemoradiotherapy may also play a role in the
pathogenesis of OB after HSC transplantation [84,85].
Bronchiolitis obliterans organizing pneumonia (BOOP)
is a disorder involving bronchioles, alveolar ducts, and
alveoli, whose lumen becomes filled with buds of granu-
lation tissue, consisting of fibroblasts and an associated
matrix of loose connective tissue. It derives from the
proliferative type, and it generally includes mild inflam-
mation of the bronchiolar walls. In contrast to BO,
there is no prominent bronchiolar wall fibrosis or
bronchiolar distortion [86]. The involvement of an
alloimmunologic reaction can be considered, although
the pathogenesis of BOOP following HSCT is poorly
understood. In animal studies, BOOP develops after a
reovirus infection. A significant role for T cells and
Th1-derived cytokines, including interferon-a, is impli-
cated in the development of disease [87]. Indeed, T-cell
depletion prevents from BO and BOOP after allogeneic
hematopoietic SC transplantation with related donors
[88]. A reported case, following syngeneic BM trans-
plantation, suggests that BOOP is not always the result
of an allogeneic immune response [89]. In other non-
HSCT settings, BOOP has been seen in association with
infection, drugs, radiation therapy, and a number of
connective tissue disorders [90]. It has also been shown
that the 2-year cumulative incidence of late-onset non-
infectious pulmonary complications (LONIPC, including
BO and BOOP) has been 10% in 438 patients under-
going HSCT. Moreover, the survival rate at 5 years has
been significantly worse in affected subjects than in
unaffected ones [91].
Graft versus host disease (GVHD) is a frequent and
lethal complication of HSCT that limits the use of this
important therapy. On the basis of pathophysiology and
appearance, GVHD is classified in acute and chronic
one [92]. Acute GVHD occurs prior to day 100 after
transplant and it consists in an enhanced inflammatory/
immune response, mediated by the competent donor’s
lymphocytes, infused into the recipient, where they react
against an environment perceived as a foreign one. The
process is amplified through the tissue release of mole-
cules which stimulate the donor’s lymphocytes. This
apparently contradictory phenomenon is simply a phy-
siological reaction of the damaged tissue to the disease
which has led to the transplant therapy [93]. Acute
GVHD presents clinical manifestations in the skin, i.e.
maculopapular rash, which can spread throughout the
body, dyskeratosis (in severe cases the skin may blister
and ulcerate) [94], in the gastrointestinal tract, i.e. diar-
rhea, emesis, anorexia, abdominal pain, mucosal ulcera-
tion with bleeding, luminal dilatation [95], and in the
liver, i.e. same liver dysfunction of veno-occlusive dis-
ease, drug toxicity, viral infection, sepsis, or iron over-
load [96]. Chronic GVHD is the major cause of late
non-relapse death following HCT [97]. However,
chronic GVHD pathophysiology is not completely
understood. Probably, thymus atrophy or dysfunction,
which can develop after pharmacological preparation of
transplant, play a major role in chronic GVHD manifes-
tation. This fact leads to a peripheral tolerance decrease
and to an increase in the number of autoreactive T lym-
phocytes. Autoreactive T lymphocytes lead to an inter-
feron gamma mediated increase in the collagen
deposition and fibrosis, a characteristic feature of
chronic GVHD [97,98]. The manifestations of chronic
GVHD are protean and often of an autoimmune nature.
Many districts are involved, i.e. skin with dyspigmenta-
tion, alopecia, poikiloderma, lichen planus-like eruptions
or sclerotic features, nails with nail dystrophy or loss,
the mouth with xerostomia, ulcers, lichen-type features,
restrictions of mouth opening from sclerosis, eyes with
dry eyes, sicca syndrome, cicatricial conjunctivitis, mus-
cles, fascia and joints with fasciitis, myositis, or joint
stiffness from contractures, the female genitalia with
vaginal sclerosis, ulcerations, the gastrointestinal tract
with anorexia, weight loss, esophageal web or structures,
liver with jaundice, transaminitis, lungs with restrictive
or obstructive defects on pulmonary function tests,
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bronchiolitis obliterans, pleural effusions, kidneys with
nephrotic syndrome (rare), heart with pericarditis and
bone marrow (thrombocytopenia, anemia, neutropenia)
[92,99,100].
Hepatic veno-occlusive disease (VOD) is another
recurrent complication after SC transplantation. VOD is
a condition in which some of the small hepatic veins are
blocked, in this case, by cells. It is a complication of
high-dose chemotherapy given before a BM transplant
and it is marked by weight gain, due to fluid retention,
increased liver size, and raised levels of bilirubin in the
blood [101,102]. VOD is more frequent in children
undergoing SC transplantation [103].Two hundred and
forty four HSCTs have been evaluated and it has been
found that VOD had appeared in 11% of them. It has
been identified that risk factors for VOD are age <6.7
years, type of VOD prophylaxis, and busulphan-contain-
ing conditioning regimens [104]. Interesting results have
been obtained in VOD treatment by oral defibrotide
[105] and combination of intravenous heparin, oral glu-
tamine and ursodiol [106].
Obstacles and possible solutions
The compatibility between the recipient and the graft is
the main problem that must be faced off when a medi-
cal group decides to transplant organs, tissues or cells
successfully. In SCT, the immunorejection also repre-
sents an important obstacle. If autogenous cells are
available, immunorejection can be bypassed. In fact,
common clinical practice is to harvest autogenous
MCSs, expand them in culture, avoiding microorganism
contamination, and store the obtained cell population
before implantation [9].
Interestingly, allogenic MCSs transplant, obviously
applied in emergency situations, such as spinal cord
injury or myocardial infarction, demonstrates high suc-
cess rates. A tolerance of allogenic MCSs seems to be
induced by the same grafted cells. Indeed, MCSs inhibit
T cell proliferation and maturation through direct cell-
cell effects and by secretion of soluble factors [107,108].
Allogenous EC transplantation is not immunotolerated
as MSCs graft. Therefore, avoiding the EC immunorejec-
tion, several strategies are being developed. Somatic cell
nuclear transfer (SCNT) is currently the most promising
of them. SCNT consists in the enucleation of the donor’s
oocytes and the renucleation of them with nuclei taken
from the patient’s somatic cells. The created cells are tol-
erated because they express major histocompatability
complex (MHC) of the recipient. The disadvantages of
SCNT include the creation and destruction of embryos
and the current inability to apply the technology in auto-
immune diseases [109]. In order to avoid autoimmune
rejection, some elaborate methods, such as gene therapy,
are under investigation [3,110].
ESCs are characterized by genetic instability and
imprinting genes dysregulation [111]. Indeed, their
transplantation in rodents is associated to higher risk of
malignant transformations, such as teratomas or terato-
carcinomas [112-114], although the tumorigenic poten-
tial of ESC seems to be greatly reduced when the cells
are predifferentiated in vitro before implantation [115].
The graft of ESCs must be preceded by an accurate
functional characterization to distinguish partially trans-
formed and potentially oncogenic clones and normal
cells [116].
Medical tourism
In developing countries some doctors are treating
patients with ASC without waiting for clinical trials to
validate the safety of using them for health problems
[117].
In treatments, involving the use of ASC, the cells are
injected into the blood, lumbar region, or damaged tis-
sue. The only treatments using ASC that are proven by
clinical trials, are concerned with blood disorders, bone
marrow transplantation and rare immune deficiencies.
Several cases of patients, who developed serious side
effects following SC transplantation, such as brain
tumors, after injections of fetal neural SC, or meningitis
have been reported [118].
A Google search, using the key words ‘’stem cell ther-
apy’’ or ‘’treatment’’, has outlined the range of treat-
ments being offered directly to consumers. Websites
generally describe therapies as safe, effective, and ready
for routine use in a wide variety of conditions. In con-
trast, the published clinical evidence has been unable to
support the use of these therapies for the routine disease
treatment. Patients must receive sufficient and appropri-
ate information and fully understand the risks. Clinics
must also contribute to public expectations without
exceeding what the field can reasonably achieve. How-
ever, this interpretation is subject to the following lim-
itations: information, available from websites, could not
be indicative of the information actually shared with
patients during their clinical encounters; the aggregate
data, collected from a heterogeneous group of clinics,
could not be used to evaluate the claims of any particu-
lar clinic; and finally, the accuracy of websites’ claims
has not been tested directly by analyzing actual outcome
data. Instead, there is a lack of high quality evidence
supporting SC clinics’ claims. Even supposing that
clinics have indeed observed successful recovery from
chronic disease post-treatment, a lack of good evidence
precludes a valid or precise inference that the observed
improvement is attributable to the interventions. If, in
fact, the interventions had not been effective, then the
patients would have been subjected to inappropriate
risks and exaggerated financial burden [119,120].
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Possible Clinical Uses
Autoimmune disease
Rheumatoid arthritis and juvenile idiopathic arthritis
Rheumatoid arthritis (RA) is the progressive and irrever-
sible erosion of the cartilage tissue of joint with the con-
sequent loss of mobility, pain and reduction in the
quality of life. Probably, RA and juvenile idiopathic
arthritis (JIA) are caused by failure of tolerance and
immune response against joint tissue antigens and
aptens with abundant release of inflammatory cytokines
and autoantibody [121,122]. Standard therapy encloses
nonsteroidal medications with slow addition of tradi-
tional disease-modifying anti-rheumatic drugs
(DMARDs) or intra-articular corticosteroid injections,
but the remission rate is only about 15% [123].
Several clinical trials have been conducted to treat RA
and JIA with autologous HSCs transplantation
(AHSCT).
A significant response has been obtained in most sub-
jects in a study involving 76 patients with severe RA
which were resistant to conventional therapies and sub-
mitted to AHSCT. Although the disease has not been
cured, recurrent or persistent disease activity has been
controlled, in some cases, with common antirheumatic
drugs [124]. A trial, involving 33 patients with severe,
refractory RA, randomly submitted to either AHSCT or
selected CD34+ infusion, has not shown any advantage
with antigen selection, but it has confirmed immunomo-
dulatory action of HSC in joint microenvironment [125].
A successfully HSCT protocol has been proposed to
treat severe JIA, harvest BM, select positive SCs, deplete
T cells, re-infuse the cells and administer antiviral drugs
and immunoglobuline until the immune system returns
to full competence to avoid frequent infection [126].
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multi-system,
inflammatory, autoimmune disease, caused by BM
microenvironment dysfunction and consequently a
marked reduction of number and proliferative capability
of HSCs with a hyperproduction of immunocomplex.
Cells CD34+ undergo an elevated apoptosis rate. SLE
includes nephritis, serositis, pneumonitis, cerebritis, vas-
culitis, anti-phospholipid antibody syndrome with
venous and vascular thrombi, arthalgias, myalgias, cuta-
neous symptoms [127]. Usually SLE is aspecifically trea-
ted with non-steroidal anti-inflammatory drugs,
antimalarials, corticosteroids and cytotoxic agents. How-
ever, every drug involves severe side effects and frequent
relapses [128].
AHSCT has reduced the number of apoptotic CD34+
cells pre-treatment [22]. In the last decade, contrasting
results have been reported in literature. AHSCT has
been performed on 15 patients with severe SLE with a
general positive outcome. Only two subjects have had a
recurrence of symptoms [129]. However, it has been
reported a lower disease free rate and high mortality
[130]. Further trials are required, but it seems probable
that HSCT can be used not with a curative intent, but
to mitigate the disease impact towards a more drug sen-
sitive type. However, it should be reserved only for
those patients with persistence of organ-threatening
SLE, despite the standard aggressive therapy [131].
Multiple sclerosis
Multiple Sclerosis (MS) is a life-threatening, physically
and psychologically debilitating autoimmune disease
(AD), mediated by T cells triggered against structural
components of myelin and consequent degenerative loss
of axon in the central nervous system (CNS). In fact,
the nerve atrophy progressively reduces the electrical
signalling neurons muscles and related mobility. The
inflammatory reaction is an important component of
MS physiopathology and the conventional treatments
aims at reducing it in order to cure or postpone course
disease [132,133]. Two types of MS can be identified:
primary progressive MS (PPMS), generally resistant to
treatment and without amelioration, and secondary pro-
gressive MS (SPMS) with episodic relapse and improve-
ment [134].
As gold standard therapy efficiently delays MS pro-
gression for many years, AHSCT have been performed
on patients who do not respond to conventional thera-
pies, and consequently the results have not been
encouraging and, in several cases, they have taken a
turn for the worse [135]. Furthermore, graft exposes
patients to infection risks, localized toxicity or autoim-
mune diseases [136,137]. However, it has been reported
a reduction of CNS inflammation with a stabilization of
the disease in patients aged less than 40 years [136].
A plastic conversion of HSC-derived cells, to replace
damage neurons, has been hypothesized [138].
Systemic sclerosis
Systemic sclerosis (SSc) is a multisystem, rare disorder
characterized by cutaneous and visceral (pulmonary,
cardiac, gastrointestinal and renal) fibrosis as a conse-
quence of T cell activation, autoantibody production,
cytokine secretion and excessive collagen deposition.
Patients with the diffuse variant, who have extensive
skin and early visceral involvement, have a poor out-
come with a 5-year mortality which is estimated at
40-50% in 5 years [139]. The therapy for the SSc is far
from being perfect. At present, the best results are
obtained with the combination of cyclophosphamide
(CY) and angiotensin [140].
It has been demonstrated that AHSCT improves the
skin flexibility and stabilizes the pulmonary involvement
[141-146].
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Farge et al. have compared two studies with conflict-
ing results. The first describes a long time remission
rate of 80% (partial or complete) on 57 patients, and the
majority of the subjects have presented a general
improvement of pre-AHSCT clinical condition. The sec-
ond study, instead, shows a higher reactivation rate
(50%). Interestingly, AHSCT can extend the short life
expectancy of patients with severe SS [147].
Ultimately, priming regimens, i.e. a disease progression
and transplant procedure, that is transplanted-related
complication, have been associated to high mortality
rates (27%) [143].
Crohn’s disease
It is an incompletely known autoimmune disease char-
acterized by the gastrointestinal loss of immune toler-
ance caused by overactive T-helper 1 response. The
environmental agents and genetic factors are also
involved. Sometimes the disease can be controlled by
immunosuppressive drugs, antibodies and surgical inter-
vention [148]. AHSCT has proved safe and can be able
to induce and maintain remission in previously refrac-
tory patients affected by Crohn’s disease [149,150].
By combining AHSCT with CY, a clinical remission
with a disappearance of diarrhea, and a reduction in the
abdominal pain and activity have been obtained [151].
Autoimmune cytopenias
In immune thrombocytopenia purpura (ITP), the platelets
are removed from blood by autoantibodies and the effects
are thrombocytopenia and bleeding. Usually, ITP cases are
responsive to high doses of immunosuppressors; neverthe-
less this treatment exposes them to myelosuppression
risks. HSCT can accelerate the reestablishment of the
hematological parameters, while the number of autoim-
mune cells in the body decreases [152]. An American
study has showed the efficacy of a combined therapy of
CY and AHSCT in chronic refractory ITP treatment. The
majority of patients show a long term response, suggesting
that SCs can accelerate the hematological re-balance com-
pared with classic immunotherapy [153]. A study by Eur-
opean Bone Marrow Transplantation (EBMT) reports the
treatment of 12 cases of ITP with AHSCT. However, the
responses to treatment have varied from a transient
response to a continuous remission or even death related
to transplantation [154]. Immune haemolytic anemia
(IHA) is a hematologic disease characterized by an early
destruction of erythrocytes due to an autoreaction of anti-
bodies or complement against the membrane protein
[155-157]. The few reports available do not permit to gain
definitive conclusions. It has been suggested that the asso-
ciation between the AHSCT and immunosuppressive ther-
apy can be an effective treatment for IHA [158]. However
it has also been showed a high failure rate or even death
after HSCT [159].
Diabetes Mellitus
Type I diabetes mellitus (DM) results in a cell-mediated
autoimmune attack against insulin-secreting pancreatic
b-cells. Insulin regulates glucose homeostasis and, in
particular, it reduces glycemia when glucose exceeds in
blood. Glucose accumulation, which is typical of dia-
betes, damages blood vessels causing the decrease of cell
perfusion. Other complications are diabetic neuropathy,
consisting of a gradual loss of hand, foot and limb
mobility caused by nerve degeneration, retinopathy,
characterized by loss of vision and blindness for light-
sensitive retina atrophy, nephropathy with a loss of
removing wastes and excess water and urinary tract
infection with a glucose rich urine which favours bac-
teria proliferation. The common therapy consists in the
chronic introduction of exogenous insulin to restore
glucose homeostasis, although resistance to this therapy
has been observed [160-163]. SC transplantation can
rehabilitate pancreatic islets and reintroduce physiologi-
cal secretion of human insulin.
AHSCT improves b-cells function and frequently
decreases the exogenous insulin need [20] or induces a
persistent insulin independence and normal glycemic
control when grafted in type 1 DM subjects [164].
Combining CY with AHSCT , an insulin-free period is
achieved [22]. In particular it has been proposed a
synergic action of CY and AHSCT to explain exogenous
insulin independence. This has been shown in the first
successful Polish attempt to achieve remission in the
early phase of type 1 diabetes mellitus following immu-
nosuppressive treatment and the subsequent AHSCT.
The method involves the destruction of the patient’s
immune system and also the autoimmune process
which is the main pathomechanism in type 1 diabetes
mellitus. As soon as the autoaggressive mechanism is
stopped, pancreatic cells might be able to resume secre-
tion of sufficient amounts of insulin to maintain normal
glucose level [165]. Allotropic human adipose tissue
derived, insulin-making mesenchymal SCs (h-AD-MSC)
have been transfused with unfractionated cultured BM
in insulinopenic DM patients without side effects.
Furthermore, an appreciable insulin requirement
decrease has been observed [166].
Neurological disorders
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ASL) is caused by the
progressive death of central and peripheral motor neu-
rons. The subjects affected by ALS show a severe motor
dysfunction. In several cases the mutation of the super-
oxide dismutase gene is inherited, but often its origin is
unknown. ALS is not a typical AD because autoimmune
and inflammatory abnormalities are not an etiological
cause of the disease, even if they influence its
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progression. The therapeutic strategy, used for ALS, is
intended to protect neurons from degeneration and to
stimulate cell regeneration. At the moment, no drug
treatment restores the neural cells. SCs therapy is a pro-
mising strategy that can combine neuroprotection with
the recovery of the neuromotor function [167].
Intrathecal injection of selected HSC or MSC have
resulted safe and have afforded a partial neurological
function improvement in patients with severe ALS
[168,169].
Ex vivo expanded AHSC spinal injection, in patients
with severe impairment of the lower limb by ALS, has
also showed cell number-related improvement of gen-
eral condition, i.e. a deceleration of the leg muscular
strength loss and a respiratory function decline. Side
effects, such as intercostal pain or dysesthesia have only
been slight and reversible, but they sometimes persist
after 2 years from treatment [170].
AHSCT into the frontal motor cortex in ALS patients
has delayed the disease progression and has improved
the quality of life [171].
Many cases of ALS patients, treated with autologous
SCs (mesenchymal and hematopoietic) and injection
(intraspinal thoracic or in motor cortex), have been
reported. A deceleration of forced vital capacity linearly
declines and an improvement in functionality has been
described, probably due to an immunomodulatory effect
[172].
Parkinson’s disease
Parkinson’s disease (PD) is a debilitating neurodegenera-
tive disorder caused by selective and gradual loss of
nigrostriatal dopamine-containing neurons [112]. Dopa-
minergic neurons are localized in the substantia nigra
pars compacta and project on to striatum. A degenera-
tion of these cells leads to neural circuit anomaly in the
basal ganglia that regulate movement. The main symp-
toms are rigidity, bradykinesia, tremor and postural
instability [173]. Pharmacological treatments, such as
levodopa/carbidopa, dopamine agonists, MAO-B inhibi-
tors, and COMT inhibitors, are effective to control PD
symptoms but they are unable to stop neural degenera-
tion and replace dead cells [174]. In this context SCs
seem to be promising since they can stimulate the
recovery of neuromotor function. PD patients, who had
received unilaterally striatum human embryonic mesen-
cephalic tissue implants twice, have showed movement
improvements (different degrees) and DOPA (dopamine
precursor) increased levels [175,176]. Symptoms and F-
fluorodopa (marked analogous) uptake have significantly
improved in PD patients younger than 60 [177].
Bilateral fetal nigral graft, in PD patients, has also
resulted safe and quite effective. Fluorodopa uptake has
increased, but in about half of the patients dyskinesia
has remained unchanged [178,179].
Spinal cord lesions
Spinal trauma can break ascending and descending axo-
nal pathways with consequent loss of neurons and glia,
inflammation and demyelination. Depending on the
injury site, functional effects, induced by cellular
damage, are inability of movement, sensorial loss and/or
lack of autonomic control. No therapies for spinal
trauma exist. However, interesting results have been
obtained with SCs transplantation [112].
Based on the discovery that olfactory mucosa is an
important and readily disposable source of stem like
progenitor cells for neural repair, the effects of its
intraspinal transplant on spinal cord injured patients
have been shown. All the patients have improved their
motor functions either upper extremities in tetraplegics
or lower extremities in paraplegics. The side effects
include a transient pain, relieved with medication, and
sensory decrease [180]. Generally, the olfactory mucosa
transplant is safe, without tumor or persistent neuro-
pathic pain [181]. Neurological improvements have also
been observed in spinal cord injury patients treated with
intra-spinal autologous BMC graft. The best results have
been obtained in patients transplanted 8 weeks before
the trauma [182].
Huntington’s disease
Huntington’s disease (HD) is a fatal, untreated autoso-
mal dominant characterized by CAG trinucleotide
repeats located in the Huntington’s gene. This neurode-
generative disorder is characterized by chorea, i.e. exces-
sive spontaneous movements and progressive dementia.
The death of the neurons of the corpus striatum causes
the main symptoms [112]. At the moment, no therapies
for HD exist although SCs can contrast the neurodegen-
eration characteristic of the disease. In a HD patient,
who died 18 months after human fetal striatal tissue
transplantation for a cardiovascular disease, postmortem
histological analysis has showed the survival of the
donor’s cells. No histological evidence of rejection has
been observed. The donor’s fetal neural cells do not
have mutated huntingtin aggregate and currently are
supposed to be able to replace the damaged host
neurons and reconstitute the damaged neuronal connec-
tions [183].
Several studies have emphasized safety [184,185], the
donor’s cells survival [183] and the functional efficacy
[186,187] of intracerebral fetal striatal transplantation
practice.
However, three cases of post-graft subdural hemato-
mas, in late-stage HD patients, have been reported. The
same authors have observed that striatal graft, in heavily
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atrophied basal ganglia, probably increases hematoma
risk [188].
Stroke
The obstruction of a cerebral artery leads to focal ische-
mia, loss of neurons and glial cells with the consequent
motor, sensory or cognitive impairments. Recent
advances in thrombolysis and in neuroprotective strate-
gies allow managing acute stroke. When drugs are admi-
nistered few minutes after the injury and the damage is
not severe, it is possible to restore the normal functions
[112]. Interesting results are also obtained with the SC
therapy.
A subarachnoidal injection of immature nervous cells
and hematopoietic tissue suspension, in patients with
brain stroke, have significantly improved the functional
activity without serious side effects [189].
Progressively, neurological deficits have decreased in
cerebral infracted patients, when treated with intrave-
nous MSCs infusion. No adverse cell-related, serological
or imaging defined effects have been observed [190].
Interesting results have been obtained with the granu-
locyte colony-stimulating factor (G-CSF) in the acute
cerebral infarction management. G-CSF has mobilized
HSCs, improving the metabolic activity and the neurolo-
gic outcomes [191].
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe reces-
sive X-linked muscular dystrophy characterized by pro-
gressive muscle degeneration, loss in ambulation,
paralysis, and finally death. DMD is caused by mutations
on the DMD gene, located on the X chromosome. DMD
symptoms are principally musculoskeletal, i.e. muscle
fiber and skeletal deformities, difficulties in motor skills
and fatigue, but they can regard one’s behavior and
learning. To date, no cures for DMD are known, while
treatments, such as corticosteroids, physical therapy and
orthopedics appliance can control the symptoms to
maximize the quality of life [192]. Recent developments
in SC research suggest the possibility to replace the
damaged muscle tissue.
Allogenic, combined with CY, or autologous myoblast
transplantation in DMD patients is a safe procedure. No
local or systemic side effects have been reported
[193,194]. In particular, using fluorescence in situ hybri-
dization (FISH), myoblast allograft has showed the
donor’s nuclei fused with the host’s nuclei and dystro-
phin wild type increased [195]. Therefore distrophin
mRNA has been detected using polymerase chain reac-
tion (PCR), six months after graft [196]. However, many
authors have reported that myoblast injection in DMD
patients do not improve their strength [194], even if
the injection site, CY dose or blast number have
changed [196,197]. An injection-triggered cellular
immune response in the host has been discovered.
The antibodies producted are capable to fix the comple-
ment and destroy new myotubes. Probably distrophin is
an antigen recognized by the host immune system [198].
Heart failure
Heart failure is commonly caused by myocardial infarc-
tion (MI). MI is the ischemic necrosis of the cardiac tis-
sue and it is frequently triggered by severe coronary
stenosis. The myocyte fall produces abnormal left-
ventricular remodelling the chamber dilatation and con-
tractile dysfunction [199]. The rapid reperfusion of the
infarct related coronary artery is the primary manage-
ment to reduce the ischemic area and avoid the myocar-
dic tissue damage. The percutaneous transluminal
coronary angioplasty, with a stent implantation, is the
gold standard method to reestablish the coronary flow.
Unfortunately, angioplasty is effective only if executed
rapidly and expertly, otherwise the myocardial necrosis,
which starts several minutes after the coronary occlu-
sion, commits the cardiac function [200]. Many studies
suggest that SCs can improve heart function by repair-
ing the cardiac tissue.
The major multicenter trial on MI treatment with
autologous skeletal myoblast transplantation, has
reported the failure of cell therapy in heart dysfunction.
No improvements in the echocardiographic heart func-
tion have been underlined, neither general health has
taken a turn for the worse [201]. However, other studies
have described the efficacy of myoblast transplant in the
ejection fraction (EF) improvement in MI patients
[202,203].
Instead, AHSCT improves cardiovascular conditions in
MI patients, such as ejection fraction, and it avoids
harmful left ventricular remodelling [204].
In particular, intracoronary infusion of HSCs is asso-
ciated with a significant reduction of the occurrence of
major adverse cardiovascular events after MI, such as
MI recurrence restenosis or arrhythmia [205,206].
Ocular surface diseases
Ocular surface diseases are characterized by persistent
epithelial defects, corneal perfusion problems, chronic
inflammation, scarring and conjunctivalisation resulting
in visual loss. These pathologies are associated with a
limbal SC deficiency (LSCD). LSCD derives from heredi-
tary disorders, such as aniridia, keratitis, or acquired dis-
orders, such as Stevenson-Johnson syndrome (SJS),
chemical injuries, ocular cicatricial pemphigoid, contact
lens-induced keratopathy, multiple surgery or limbal
region cryotherapy , neurotrophic keratopathy and per-
ipheral ulcerative keratitis conditions [207]. Obviously,
SC transplantation is the only effective therapy that can
restore the ocular environment.
A study conducted on a homogeneous group of
patients with limbal cell deficiency has been conducted
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using SCs obtained from the limbus of the contralateral
eye. Fibrin cultures were grafted onto damaged corneas
observing that: 1) fibrin-cultured limbal SCs were suc-
cessful in 14 of 18 patients; 2) re-epithelialization
occurred within the first week; 3) inflammation and vas-
cularization regressed within the first 3-4 weeks; 4) by
the first month, the corneal surface was covered by a
transparent, normal-looking epithelium; 4) at 12-27
months follow-up, corneal surfaces were clinically and
cytologically stable. Their visual acuity improved from
light perception or counting fingers to 0.8-1.0 [208].
Limbal allograft also corrects acquired and hereditary
LSCD recovering the visual activity [209-211]. It has
been reported a retrospective study on endothelial rejec-
tion in central penetrating graft after a simultaneous
keratolimbal allograft transplantation (KLAT) and pene-
trating keratoplasty (PKP) using the same donor’s cor-
nea. A third cohort of treated patients have rejected
transplant. After an immunosuppressive therapy, the
majority of rejects have restored the corneal clarity
while in the others neovascularization has developed
into the grafted limbs [212].
Cartilage repair
Osteoarthritis (OA) is a degenerative joint disease, char-
acterized by accumulated mechanical stresses to joints
and leading to the destruction of articular cartilage.
A synovial fluid decrease has also been observed [213].
OA and peripheral joint injuries are commonly treated
with interventional pain practice, exercise therapy, ultra-
sound or electromagnetic device after surgery, although
these therapies have not proven to be a definitive solu-
tion [214-217]. SCs seem to be a promising solution to
overcome OA cartilage destruction. The first autologous
mesenchymal SC culture and percutaneous injection
into a knee with symptomatic and radiographic degen-
erative joint disease has been reported and it has
resulted in significant cartilage growth, decreased pain
and increased joint mobility. This has significant future
implications for minimally invasive treatment of osteoar-
thritis and meniscal injury treated with percutaneous
injection of autologous MSCs expanded ex-vivo has
been reported [218].
Liver disease
Cirrhosis is a progressive liver function loss caused by
fibrous scar tissue replacement of normal parenchyma.
Cirrhosis is commonly caused by alcoholism, hepatitis B
and C and fatty liver disease, but there are many other
possible causes. Cirrhosis is generally irreversible and
treatments are generally focused on preventing its pro-
gression and complications. Only liver transplant can
revert the pathological condition if there is a terminally
ill patient [219]. SC therapy can contrast liver degenera-
tion and block cirrhosis progression.
AHSC infusion in cirrhotic patients has improved liver
parameters, such as transaminase, bilirubin decrease and
albumin increase [220,221]. After infusion, proliferation
indexes, such as alpha fetoprotein and proliferating cell
nuclear antigen (PCNA), have significantly increased,
suggesting that HSCs can enhance and accelerate
hepatic regeneration [222]. No significant side effects
have been registered [223].
Cancer
Renal cell cancer
Renal cell cancer (RCC) is the most frequent kidney
cancer. RCC originates in the lining of the proximal
convoluted renal tubule. RCC appears as a yellowish,
multilobulated tumor in the renal cortex, which fre-
quently contains zones of necrosis, hemorrhage and
scarring. The signs may include blood in the urine, loin
pain, abdominal mass, anaemia, varicocele, vision
abnormalities, pallor, hirsutism, constipation, hyperten-
sion, hypercalcemia, night sweats and severe weight loss.
The initial treatment is commonly a radical or partial
nephrectomy. Other treatment strategies, including hor-
mone therapy, chemotherapy, and immunotherapy, have
little impact on global survival [224,225]. HSCT can be
an important tool for the management of RCC, in parti-
cular under the metastatic form.
HSCT, combined with the immunosuppressive or
donor’s lymphocyte infusion (DLI), can improve the
general condition in metastatic RCC patients. Three fac-
tors, i.e. performance status, C-reactive protein (CRP)
level and lactate dehydrogenase (LDH) level, have been
found and they are significantly associated with a major
success of allograft [226]. HSCT have trigged graft ver-
sus tumor (GVT) response, reducing the metastasis and
reaching out the survival time [227-229].
Breast cancer
Breast cancer (BR) refers to cancers originating from the
breast tissue, commonly from the inner lining of milk
ducts or the lobules that supply the ducts with milk.
Occasionally, BR presents as a metastatic disease with
spreads in bones, liver, brain and lungs. The first evi-
dence or subjective sign of BR is typically a lump that
feels different from the rest of the breast tissue. Other
symptoms can be: changes in breast size or shape, skin
dimpling, nipple inversion, or spontaneous single-nipple
discharge. Pain ("mastodynia”) is an unreliable tool to
determine the presence or absence of BR, but it may be
indicative of other breast health issues. When the cancer
cells invade the dermal lymphatics (small lymph vessels)
in the breast skin, BR appears as a cutaneous inflamma-
tion. In this phase symptoms include pain, swelling,
warmth and redness throughout the breast, as well as an
orange peel texture to the skin, referred to as “peau
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d’orange”. Treatment includes surgery, drugs (hormonal
therapy and chemotherapy), and radiation, which are
effective against non metastatic forms [230]. SCT can
increase survival in patients with spreading BR.
A high dose chemotherapy (HDC) with SC support
has improved the disease free survival in metastatic BR.
However, HDC has induced serious cytotoxicities [231].
In reduced intensity conditioning regimens (RICT), allo-
geneic HSCT has proven to be effective in persistent
and progressive metastatic BR, decreasing relapse. Allo-
geneic SC transplantation with myeloablative condition-
ing regimens may provide cytoreduction and eradication
of disease with a cancer free-graft and an immune-
mediated graft-versus-tumor (GVT) effect mediated by
the donor’s immune cells [232,233].
Colorectal cancer
Colorectal cancer (CRC) includes cancerous growths in
the colon, rectum and appendix. Many CRCs are
thought to arise from adenomatous polyps in the colon.
These mushroom like growths are usually benign, but
some may develop into cancer over time. Symptoms
and signs are divided into: local ones, consisting in
change in bowel habits and in frequency, such as consti-
pation and/or diarrhea, feeling of incomplete defecation
(tenesmus) and reduction in tool diameter, bloody stools
or rectal bleeding, stools with mucus, black and tar-like
stool (melena), bowel pain, bloating and vomiting,
hematuria or pneumaturia, or smelly vaginal discharge;
constitutional ones i.e. weight loss, anemia, dizziness,
fatigue and palpitations; metastatic ones, i.e. liver metas-
tases, causing Jaundice, pain in the abdomen, liver enlar-
gement and blood clots in veins and arteries. Surgery is
the usual therapy and, in many cases, is followed by
chemotherapy [234-236]. The gastrointestinal tract is a
target of GVHD in transplants and, therefore, CRC,
might be treated by allogeneic SCT. Four cases of meta-
static CRC, undergoing reduced-intensity SC transplan-
tation (RIST), have been reported. No significant graft
toxicities have been registered. CRC markers have
decreased in three patients after allograft. Three patients
died of disease progression, but postmortem examina-
tion has showed a macroscopic metastatic lesion disap-
pearance [237]. The patients with progressing metastatic
CRC, treated with RIST, have showed relevant results in
terms of tumor response. Even metastatic CRC need
intense GVT to eradicate spreading tumor cells. Allo-
geneic SCT is likely to have trigged the generation of
anti-neoplastic T cells [238-240].
Ovarian cancer
Ovarian cancer (OC) is a cancerous growth arising from
different parts of the ovary. Commonly, OC arises from
the outer lining of the ovary, but also from the Fallopian
tube or egg cells. OC is characterized by non-specific
symptoms and, in early stages, it is associated with
abdominal distension. Many women with OC report one
or more non-specific symptoms, such as an abdominal
pain or discomfort, an abdominal mass, bloating, back
pain, urinary urgency, constipation, tiredness, and some
specific symptoms, such as pelvic pain, abnormal vaginal
bleeding or involuntary weight loss. There can be a
build-up of fluid (ascites) in the abdominal cavity.
A surgical treatment may be sufficient for malignant
tumors that are well-differentiated and confined to the
ovary. An addition of chemotherapy may be required for
the most aggressive tumors that are confined to the
ovary. For patients with an advanced disease, a surgical
reduction is combined with a standard chemotherapy
regimen. Some studies describe the feasibility of the
combination of chemotherapy with SCT [241].
Allogeneic HSCT, associated with chemotherapy in
advanced OC, treatment has induced variable effects.
When SCs infusion trigger GVT, it is possible to control
the disease progression [242,243]. However, GVT does
not occur frequently. No serious side effects have been
registered [244,245].
Lung cancer (LC)
LC is characterized by an uncontrolled cell growth in
the lung tissue. Frequently LC rises from the epithelial
cells. The small cell lung carcinoma (SCLC) is the most
frequent lung carcinoma. The symptoms can result from
the local growth of the tumor (coughing up blood,
shortness of breath and chest pain), a spread to the
nearby areas (hoarseness of voice, shortness of breath,
difficulty in swallowing, swelling of the face and hands),
a distant spread (the spread to the brain can cause head-
ache, blurring of vision, nausea, vomiting, and weakness
of any limb, a spread to the vertebral column which can
cause back pain, a spread to the spinal cord which can
cause paralysis, a spread to the bone that may lead to
bone pain and a spread to the liver possibly causing
pain in the right upper part of the abdomen), paraneo-
plastic syndromes, or a combination of them. Possible
treatments are surgery, chemotherapy, and radiotherapy
[246]. An addition of SCT can improve the survival rate
and avoid relapses. AHSCT has been frequently com-
bined with chemotherapy in SCLC treatment. The rea-
son is that HSCs drastically reduce the chemotherapy
side effects, in particular myeloablation [247-249]. Prob-
ably, HSCs may also induce therapeutic effects contrast-
ing the tumor directly [250]. In SCLC, HSCs trigger
GVT and increase the survival rate.
Leukemia
Leukemia is the uncontrolled proliferation of the mye-
loid or lymphoid blood line and the consequential blast
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accumulation in the BM. Leukemia can be classified in
acute myeloid leukemia (AML), chronic myeloid leuke-
mia (CML), acute lymphoblastic leukemia (ALL) and
chronic lymphocytic leukemia (CLL). Leukemia is
caused by a mutation in the gene involved in the cell
proliferation. The first signs and symptoms of leukemia
are nonspecific and they include fatigue, malaise, and
abnormal bleeding, excessive bruising, weakness,
reduced exercise tolerance, weight loss, bone or joint
pain, infection and fever, abdominal pain or “fullness”,
enlarged spleen, lymph nodes and liver,. Moreover a
high white blood cell count is detectable. Chemotherapy
is the initial treatment of choice, but only with the sub-
stitution of the malignant blast with the normal SCs,
leukemia can be eradicated [251-256].
Many studies indicate allogenic RIST as an important
procedure to achieve a complete remission in patients
with leukemia, especially if a human leukocyte antigen
compatible donor is employed [257-265]. GVHD is the
major limiting factor for successful transplantation, but
its frequency is sensibly reduced if compared to the first
treatment [266,267]. The mortality rate has also
decreased significantly [268].
Guidelines For Scs Application
SCs transplantation in human patients must ensure
safety and therapeutic efficacy. Preclinical studies aim at
providing persuasive evidence, in an appropriate in vitro
and/or animal model, which supports the likelihood of a
relevant positive clinical outcome. Preclinical testing in
animal models, whenever feasible, is especially important
for SC based approaches because SCs can act through
multiple mechanisms. Physiological integration and
long-lived tissue reconstitution are hallmarks of SC
based therapeutics for many disease applications. Ani-
mal models will be important to assess possible adverse
effects of implanted cellular products. The need for ani-
mal model is especially strong in the case of extensive
ex vivo manipulation of cells and/or when the cells have
been derived from pluripotent SCs.
It should be acknowledged, however, that preclinical
assays, including studies in animal models, may provide
limited insight into how transplanted human cells will
behave in human recipients due to the context depen-
dent nature of the cell behavior and recipient’s immune
response. These uncertainties must be borne in mind
during the independent peer review of the preclinical
data. Only when the compelling preclinical data are
available, careful and incremental testing in patients is
justified. Preclinical studies must be subject to rigorous
and independent peer review and regulatory oversight
prior to the initiation of the clinical trials, in order to
ensure that the performance of the clinical studies is
scientifically and medically warranted. Because new and
unforeseen safety concerns may arise with the clinical
translation, frequent interaction, between preclinical and
clinical investigators, is strongly encouraged. The clini-
cal trials of SC based interventions must follow interna-
tionally accepted principles governing the ethical
conduct of the clinical research and the protection of
the human subjects. Key requirements include regula-
tory oversight, peer review by an expert panel indepen-
dent of the investigators and sponsors, fair subject
selection, informed consent and patient monitoring.
However, there is a number of important SC related
issues that merit a special attention [269]. The guide-
lines concerning the preclinical studies (animal model),
clinical studies have been summarized in the “Guide-
lines for the Clinical Translation of Stem Cells” pub-
lished in 2008.
Conclusions
This review shows the most interesting clinical trials in
SC biology and regenerative medicine [270-272]. Pro-
mising results have been described in disorders, such as
diabetes [273] and neurodegenerative diseases [274,275],
where SCs graft can reestablish one or more deficit cel-
lular lineages and, generally, a healthy state. Notably,
many clinical studies have underlined the immunomo-
dulatory effect of SCs in autoimmune diseases, such as
multiple sclerosis [275], organ transplants [276] and in
uncontrolled immune-inflammatory reactions [277-279].
Probably, SCs induce immune suppression and inhibit
proliferation of alloreactive T cells [280]. Moreover, SCs
are at the core of the huge framework of cellular ther-
apy and are going to be used in the gene therapy
[281,282] or as scaffolds in SCNT [109]. An interesting
cell type is the induced pluripotent stem cell (iPSC)
[283]. iPSCs are artificial cells derived from non pluripo-
tent cells, typically adult somatic cells through the
induction of a “forced” expression of specific genes.
iPSCs have been regarded as the most promising way
to create SCs. However the use of iPSCs has raised con-
cerns. The iPSCs are easily created by modulating the
human genome to ectopically express transcriptional
factors. Since their overexpression has been associated
with tumorigenesis [284,285], there is a risk that the dif-
ferentiated cells might also be tumorigenic when trans-
planted into patients. The insertion of transgenes into
functional genes of the human genome can be detri-
mental [286]. Furthermore, although the transcription
factors are mostly silenced following reprogramming, it
has been reported that residual transgene expression
may be responsible for some of the differences between
ESCs and iPSCs such as the altered differentiation
potential of iPSCs into functional cell types [287]. There
are a few ways of creating iPSCs, i.e. genomic modifica-
tion, protein introduction, and treatment with chemical
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reagents [288,289]. iPSCs research has to be conducted
keeping in mind ethical, legal, and social issues [290].
These cells may be used to construct disease models
and to screen effective and safe drugs, as well as to treat
patients through the cell transplantation therapy [281].
However, the validity of these predictions will depend
on the benefits obtained on the ongoing phase II and III
human clinical trials. In the meantime, new candidate
small molecules and bioactives will be identified using
SC assays in the high-throughput screening that will
impact on SC mobilization broaden the horizons of
regenerative medicine. It has been proposed that cente-
narians and supercentenarians (aged 110 years or more)
may present an unprecedented opportunity to explore
the possibilities of SCs that have proven their value over
time. These SCs should be studied to determine their
developmental potential, mutational load, telomere
lengths, and markers of “stemness” [291]. In conclusion,
beyond the great enthusiasm for new treatment perspec-
tives, an heavy investigational work is still in progress to
develop specific SCs related pharmacology. In fact new
drugs are urgently needed to assist SCs in vitro/in vivo
differentiation and full tissue/organ integration and
recovery. As far as CNS related diseases (cerebrovascular
accidents and spinal traumatic lesions) are concerned,
the role of autologous cytokines induced by SCs infu-
sion has to be deeply investigated and may represent, in
the future, a new treatment perspective.
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Muscular Dystrophy; (EF): Ejection Fraction; (EC): Embryonic cell; (EGC):
Embryonic Germ Cell; (ESC): Embryonic Stem Cell; (EBMT): European Bone
Marrow Transplantation; (FSC): Fetal Stem Cell; (GVHD): Graft Versus Host
Disease; (GVT): Graft Versus Tumor; (HSC): Haematopoietic Stem Cell; (HDC):
High-Dose Chemotherapy; (HSCT): HSC Transplantation; (h-AD-MSC): Human
Adipose-Tissue-Derived insulin-making Mesenchymal SCs; (HD): Huntington’s
Disease; (IHA): Immune Haemolytic Anemia; (ITP): Immune
Thrombocytopenia Purpura; (iPSC): Induced Pluripotent Stem Cell; (ICM):
Inner Cell Mass; (JIA): Juvenile Idiopathic Arthritis; (KLAT): Keratolimbal
Allograft Transplantation; (LDH): Lactate Dehydrogenase; (LONIPC): Late-
Onset Non-Infectious Pulmonary Complications; (LSCD): Limbal SC
Deficiency; (LC): Lung Cancer; (MHC): Major Histocompatability Complex;
(MSC): Mesenchimal Stem Cell; (MS): Multiple Sclerosis; (MI): Myocardial
Infarction; (OB): Obliterative Bronchiolitis; (OA): Osteoarthritis; (OC): Ovarian
Cancer; (PD): Parkinson’s Disease; (PCR): Polymerase Chain Reaction; (PPMS):
Primary Progressive MS; (PCNA): Proliferating Cell Nuclear Antigen; (RIST):
Reduced-Intensity Stem-Cell Transplantation; (RICT): Reduced-Intensity
Conditioning Regimens; (REB): Research Ethics Board; (RA): Rheumatoid
Arthritis; (RCC): Renal Cell Cancer; (SPMS): Secondary Progressive MS; (SCNT):
Somatic Cell Nuclear Transfer; (SCLC): Small Cell Lung Carcinoma; (SC): Stem
Cell; (SCOC): Stem Cell Oversight Committee; (SF): Synovial Fluid; (SLE):
Systemic Lupus Erythematosus; (SSc): Systemic Sclerosis; (UCE): Umbilical
Cord Epithelium; (UCB): Umbilical Cord Blood; (UC-HS): Umbilical Cord
Hematopoietic; (UC-MS): Umbilical Cord Mesenchymal; (VOD): Veno-
Occlusive Disease;
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